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Abstract
Background: The Happy Life Club™ is an intervention that utilises health coaches trained in behavioural change
and motivational interviewing techniques to assist with the management of type 2 diabetes mellitus (T2DM) in
primary care settings in China. Health coaches will support participants to improve modifiable risk factors and
adhere to effective self-management treatments associated with T2DM.
Methods/Design: A cluster randomised controlled trial involving 22 Community Health Centres (CHCs) in Fengtai
District of Beijing, China. CHCs will be randomised into a control or intervention group, facilitating recruitment of at
least 1320 individual participants with T2DM into the study. Participants in the intervention group will receive a
combination of both telephone and face-to-face health coaching over 18 months, in addition to usual care
received by the control group. Health coaching will be performed by CHC doctors and nurses certified in coach-
assisted chronic disease management. Outcomes will be assessed at baseline and again at 6, 12 and 18 months by
means of a clinical health check and self-administered questionnaire. The primary outcome measure is HbA1c level.
Secondary outcomes include metabolic, physiological and psychological variables.
Discussion: This cluster RCT has been developed to suit the Chinese health care system and will contribute to the
evidence base for the management of patients with T2DM. With a strong focus on self-management and health
coach support, the study has the potential to be adapted to other chronic diseases, as well as other regions of
China.
Trial Registration: Current Controlled Trials ISRCTN01010526
Background
Over the last decade, chronic illness prevention and
management has emerged as a critical issue in the
health of populations. The World Health Organisation
(WHO) has estimated that cardiovascular diseases
(CVD), type 2 diabetes mellitus (T2DM), chronic
respiratory diseases and cancers account for 60% of all
global deaths [1]. This figure represents 35 million
deaths annually and is expected to increase by 17% over
the next 10 years [1]. Yet many of these conditions are
partly influenced by modifiable risk factors; smoking,
sedentary behaviour, low consumption of fruit and
vegetables and high alcohol consumption [2]. The
WHO have estimated that up to 80% of new cases of
T2DM, CVD, and stroke could be prevented by redu-
cing behavioural risk factors and have called for ‘...
interventions to reduce the main shared modifiable risk
factors for noncommunicable diseases: tobacco use,
unhealthy diets, physical inactivity and harmful use of
alcohol.’ [1]. The Happy Life Club™, described in this
paper, is one such intervention, and utilises health coa-
ches trained in behavioural change principles and moti-
vational interviewing (MI) techniques to address the
management of T2DM. Health coaches aim to support
participants to improve modifiable risk factors and
adhere to effective self-management treatments asso-
ciated with T2DM. The current paper will present
details of the study design and research protocols of the
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mary care settings in China.
T2DM is among the most serious health problem
affecting the population in China and poses a significant
public health issue for the community [3]. As a result of
economic development in the past two decades, the Chi-
nese population has experienced marked changes in life-
style. For example, between 1992 and 2002 the combined
prevalence of overweight and obesity increased from
14.6% to 21.8% [4], and physical activity among Chinese
adults fell by 32% over the period 1991 to 2006 [5].
These changes have been associated with the increases
chronic diseases such as T2DM and CVD [3,4]. The
Fourth National Health Service Survey, conducted in
2008 by the China Ministry of Health, revealed that cases
of T2DM and hypertension have more than tripled over
the previous decade [6]. Recently published data reveal
that the age-standardised prevalence of total diabetes
(which included both previously diagnosed diabetes and
previously undiagnosed diabetes) and pre-diabetes were
9.7% and 15.5% respectively, accounting for 92.4 million
adults with diabetes and 148.2 million adults with
pre-diabetes [7]. According to the International Diabetes
Federation, these latest prevalence figures will mean
healthcare expenditure on diabetes in China this year will
increase by at least US$1.9 billion, reaching a total of US
$6.9 billion [8]. In addition, China has a rapidly ageing
population, largely driven by the one child policy, with
the associated potential increased burden of chronic dis-
eases [9]. By 2040 around 25% of China’s population will
be aged 65 years and over [10].
In urban China, the health care system features three
levels of health providers: community health, district
hospitals, and tertiary teaching hospitals. The majority
of outpatient care is provided by Community Health
Centres (CHCs) and their affiliated community health
stations (61.8%) [11]. Primarily owned and managed by
the government, the primary role of these community
health services is to provide public health, essential
medical treatments, preventive health care, and health
education to local communities [12]. On average, Chi-
nese residents access community health services 4.4
times per year, with individuals aged 60+ years accessing
community health services 7.3 times per year [13].
Patients with T2DM are predominantly managed by
doctors at CHCs and the majority of patients incur out-
of-pocket expenses for both medical and pharmaceutical
services. However, there is a growing recognition from
the Chinese government of the need to adopt best-
practice medical management, including the provision
of diabetes self-care education and the promotion of
healthy lifestyle choices [14].
In most countries, T2DM is managed in primary care
settings and clinical practice guidelines recognise the
importance of a structured and systematic approach that
involves a medical care team, including doctors, nurses
and dietitians, as well as patients in the management of
the condition [15]. As lifestyle changes are fundamental
to the management of T2DM [16], health care teams
require skills in both counselling and behaviour change
in order to work with the patient to achieve their goals
and ensure adherence to recommendations [17]. How-
ever skills in these areas are often limited and it has
been recognised that training in tailored approaches to
counselling, provided by techniques such as MI [18],
have the potential to improve lifestyle changes in people
with chronic illnesses [19]. MI is a directive, client-
centred counselling style for eliciting behaviour change
by helping clients to explore and resolve ambivalence
[ 1 8 ] .I ti n v o l v e sac o m p l e xs e to fs k i l l st h a tg r o wa n d
develop through disciplined practice with feedback and
coaching from a knowledgeable guide [20]. MI has been
shown to be effective in improving glycaemic control in
adults with T2DM [21]. The Happy Life Club™ uses MI
delivered by health coaches to assist patients with dia-
betes in the management of their condition.
Development of the Happy Life Club™
The Happy Life Club™ is an adaptation of a diabetes
intervention delivered in Australia, the Good Life Club
[22]. Patients with T2DM were referred to the Club by
their doctor and once enrolled received monthly tele-
phone coaching by a health care practitioner trained in
MI and behaviour change techniques. The Happy Life
Club™ similarly uses telephone coaching and in addi-
tion has face-to-face coaching by nurses and doctors
trained in MI and behaviour change techniques. Our
evaluation of the Good Life Club revealed that partici-
pants preferred to have face-to-face coaching at least in
the early phases of the intervention [23].
A pilot study was carried out in five community health
stations in the Fangzhuang district of Beijing, China
[24]. To assess the feasibility and implementation of the
H a p p yL i f eC l u b ™ trial design, participants were ran-
domly allocated into either:
1. Intervention group where patients with T2DM
received 12 months of health coaching in combina-
tion with usual care.
2. Control group where patients with T2DM
received usual care only.
In total, one hundred participants (20 per community
health station) aged 50 years and over were recruited
into the study. Participants in the intervention group
received a maximum of 19 telephone coaching sessions
and 18 face-to-face coaching sessions over the 12 month
period. In the first two months of the intervention,
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lasting 30 minutes per session and four telephone con-
tacts lasting 20 minutes per session. The frequency of
contact decreased over the 12 month period as partici-
pants gained skills and confidence in self-management.
T h ep i l o ts t u d ye n a b l e dt h ee s t a b l i s h e dt r i a lm a n a g e -
ment procedures, piloted questionnaires, measured com-
pliance and standardised operating procedures. Results
from analyses of the pilot study demonstrated that parti-
cipants in the intervention group had significant
improvements in triglyceride levels. Improvements were
also made in blood glucose monitoring, adherence to
medication, physical activity and psychosocial distress.
Trial objective
To determine the effectiveness of the Happy Life Club™
intervention in improving the HbA1c level and meta-
bolic, physiological and psychological profiles of partici-
pants at 6, 12 and 18 months compared with usual care.
Methods
Trial design
The current study is an evaluation of the Happy Life
Club™, through an 18-month cluster randomised
controlled trial (RCT). Cluster randomised sampling of
community health stations was chosen to minimise
experimental contamination between the control and
intervention participants [25]. The Happy Life Club™
trial is managed jointly by Monash University - Mel-
bourne, Peking University - Beijing and Fengtai Health
Bureau - Beijing. The study protocol was approved by
Monash University Human Research Ethics Committee.
CHCs will be randomly allocated to one of two
groups:
1. Intervention group where patients with T2DM
receive 18 months of health coaching in combina-
tion with usual care.
2. Control group where patients with T2DM receive
18 months of usual care only.
Study population & setting
The study will be implemented at CHCs in the Fengtai
District of Beijing, China. This district is a large residential
community in southwest Beijing with a population of
1.823 million residents and an average life expectancy of
78.7 years [26]. Conveniently located within communities,
CHCs deliver primary health care and basic health care to
Fengtai residents. The socio-demographic profile of resi-
dents in Fengtai varies according to geographic location.
West Fengtai is predominantly a regional/rural area; Cen-
tral Fengtai is a residential suburban area; and East Fengtai
is an urban area located near downtown Beijing.
Recruitment process
Figure 1 details the recruitment and randomisation of
CHCs and patients into the study. As shown in Figure 1,
a list of T2DM patients from each CHC will be generated
prior to CHC randomisation, and eligible patients will be
contacted by mail.
CHCs will then be randomly assigned to the control
(usual care) or intervention group (usual care plus
health coaching). Upon recruitment, participants will
receive a baseline assessment. All participants will
receive clinical assessment at 6, 12 and 18 months.
Participants
An independent person at each participating CHC will
identify eligible participants from the patient health
records maintained at each site. Patients with T2DM
will be eligible to participate if they are aged 50 years
and over, reside in the Fengtai district, have an estab-
lished health record and are receiving care at one of the
participating CHCs. Exclusion criteria include the inabil-
ity to understand and provide informed consent (e.g.,
people with cognitive problems), or a medical condition
that precludes adherence to recommendations (e.g., end
stage cancer, severe mental illness). All eligible partici-
pants will be sent an explanatory statement and consent
 
Community Health Service Cluster 
Randomisation
Control group Intervention group
Generate lists of patients 
from patient records
Apply inclusion/exclusion 
criteria
Mail out invitation letters &
consent forms to eligible patients
Baseline assessment of 
consenting participants
Intervention
- usual care
- delivery of health coach 
intervention (via telephone and 
face to face) over 18 months
- clinical tests at 6, 12 & 18 months
Control
- usual care only
- clinical tests at 6, 12 & 18 
months 
Figure 1 Flow chart of the recruitment and randomisation of
community health centres and participants.
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Page 3 of 9form, either by mail to their home address or in person
at their next community health visit. Those wishing to
p a r t i c i p a t ei nt h es t u d yw i l lb ea s k e dt or e t u r nt h e
signed consent form to their CHC. All consenting parti-
cipants will be allocated an ID number will be asked to
return to their CHC for the baseline clinical health
check. As participation in the trial will require no pay-
ment by the participants, we expect that this will pro-
vide a high incentive as patients are usually required to
pay for CHC visits in China.
Community Health Centres
As a result of extensive consultation with both the
Beijing Health Bureau and Fengtai Health Bureau, it
has been agreed that all CHCs located in the Fengtai
district will participate in the study, that is, 22 CHCs
will be involved in the implementation of the study. An
information session will be conducted for all CHC staff,
which will thoroughly explain the administrative and
implementation aspects of the study. In addition, a
member of the research team will visit each CHC to
meet with staff and answer specific questions in relation
to the study.
Randomisation
Randomisation will be performed prior to baseline
assessment of participants and CHCs will be the unit of
randomisation. A member of the research team, blinded
to CHC identity, will be responsible for central rando-
misation. Firstly, CHCs will be stratified by geographical
location (east, central, and west) in order to achieve
balanced groups according to socioeconomic status. Fol-
lowing stratification, CHCs will be randomly allocated
into the control or intervention groups using block ran-
domisation by computerised random allocation software.
Sample size
Based on conventional methods for estimating a suffi-
cient sample size in a randomised trial with two condi-
tions, and assuming that individuals are randomised to
conditions, the number of participants needed is deter-
mined mainly by three parameters [27]. These para-
meters are: (1) the tolerable Type I error rate (assuming
the null hypothesis); (2) the desired level of statistical
power (assuming the alternative hypothesis); and (3) an
anticipated effect size for a relevant test statistic (e.g.,
standardised mean difference). Consistent with general
conventions, [27] the current study specified a 5% Type
I error rate as tolerable and required 80% power. The
primary outcome measure was glycosylated haemoglobin
(HbA1c), measured on a continuous scale, and a recent
meta-analysis evaluating psychological interventions to
improve glycaemic control in patients with T2DM [21]
indicates an expected standard i s e de f f e c to f0 . 3 2a c r o s s
studies. This was the anticipated effect size estimate spe-
cified in the current investigation. Based on these para-
meters, and using the G*Power 3.1 program [28] to
conduct calculations, it was ascertained that a sample
size of n = 306 (153 per group) would be sufficient to
detect an effect size of 0.32 with 80% power, while
maintaining 5% Type I error.
As noted, the sample size calculations reported above
assume that individuals are randomised to groups. In
contrast, cluster randomisation, as used in the current
study, is associated with less statistical power; especially
when individuals within clusters are similar [29]. This
degree of similarity is quantified by the Intra-Class Cor-
relation (ICC) coefficient, which can then be used, along
with estimates of the average cluster size (in terms of
number of participants per cluster) [30] to calculate an
adjusted sample size; inflated to yield the same level of
statistical power as if individual randomisation was used
[29]. Only a limited number of clusters were available to
the current study, and estimates were calculated assum-
ing this fixed number (k = 22). As described by Camp-
bell et al. (2000), ICCs for outcome variables in primary
care research are generally lower than 0.05, and this
value was also specified in the adjusted calculations.
A sample size calculator for cluster-randomised trials is
available [29] and was used to estimate the required
sample size given cluster randomisation. Allowing for a
participant attrition rate of 20%, it was estimated a total
sample of n = 1320 would be required to achieve at
least 80% power, while maintaining 5% Type I error.
This figure reflects 60 patients per CHC (cluster), and
660 per intervention group.
Outcome assessment
The trial will run for 18 months and outcome measure-
ments will be assessed at baseline, and again at 6, 12
and 18 months by means of a clinical health check and
a self-administered questionnaire. Anthropometric, and
blood pressure measurements as well as fasting blood
samples, will be taken by independent doctors and
nurses from Peking University, who are blinded to
group allocation. All participants will be instructed to
fast overnight prior to each clinical health check for a
minimum of eight hours. Blood samples will be analysed
centrally at the CHC Laboratory blinded to group
allocation.
Physical Examination
1. Anthropometric measurements: Weight will be
measured by a beam balance scale and height by a
stadiometer attached to a wall. BMI will be calcu-
l a t e da sw e i g h t( k g )d i v i d e db yh e i g h ts q u a r e d( m
2)
and waist circumference (cm) is measured at the
level midway between the lowest rib margin and the
iliac crest.
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sure will be measured in a sitting position using a
mercury sphygmomanometer and measurements will
be taken from the right arm. Subjects will be asked
to rest for at least 5 minutes before measurements
are taken. The first phase of Korotkoff sounds will
be recorded as the systolic blood pressure, and the
fifth phase as the diastolic blood pressure.
3. Fasting blood samples:
￿ A Hitachi 7060C Automatic Biochemistry Ana-
lysis System will be used to measure fasting
plasma glucose, 2 hour postprandial glucose,
homocysteine, total cholesterol, triglyceride, and
high-density lipoprotein (HDL) cholesterol by
standard enzymatic methods. A direct HDL cho-
lesterol method will used.
￿ Low-density lipoprotein (LDL) will be calcu-
lated using the Friedewald formula [31]. LDL cal-
culations will not performed if the triglyceride
level is >4.5 mmol/L.
￿ HbA1c will be measured by a Bayer Healthcare
DCA 2000+ analyser.
According to the Chinese Guidelines for Diabetes Pre-
vention and Management [32], the cut-off points of
1.5 mmol/L, 4.5 mmol/L, 2.6 mmol/L, and 1.1 mmol/L
will be used in reporting elevated triglycerides, and total,
LDL, and HDL cholesterol values. Those having systolic
blood pressure (SBP) higher than 130 mmHg and those
having diastolic blood pressure (DBP) higher than
80 mmHg will be regarded as having elevated values [33].
Participants with BMI <24 kg/m
2 will be regarded as being
of normal weight, ≥24 kg/m
2 but <28 kg/m
2 as overweight,
and ≥28 kg/m
2 as obese [34,35]. Waist circumference
beyond 85cm for men and beyond 80cm for women will
be used as the cut-off points for central obesity [34,35].
Self Administered Questionnaire
The self administered questionnaire will be completed by
participants at each clinical health check. The question-
naire covers the following areas: the participant’sb a c k -
ground information and socio-economic status, use of
health services and health status [36], smoking status [37],
alcohol intake [38], psychosocial distress [39,40], quality of
life [41,42], diabetes self-care activities [43,44], diabetes
management self efficacy [45,46], as well as self rated
health which will be measured by SF-1, the first question
of the SF-36 [47,48]. All measures used in the question-
naire have previously adapted to suit the Chinese context
and have been validated in Chinese populations.
Intervention
Control group
Participants in the control group will receive usual care
from their CHC. This may include referral to diabetes
specialists, traditional Chinese medicine physicians, and
physiotherapists which form part of standard care as
outlined in the Chinese Guideline for Diabetes Preven-
tion and Management [32]. Participants in the control
g r o u pw i l lu n d e r g oa s s e s s m e n ta tb a s e l i n e ,a n da g a i na t
6, 12 and 18 months. All control group participants will
be informed of their results.
Intervention group
Participants who are assigned to the intervention group
will receive a combination of telephone and face-to-face
health coaching in addition to usual care from their
CHC. The health coaching will be performed by experi-
enced clinicians (community doctors and nurses). Prior
to commencing work on the intervention phase, all
health coaches will be required to complete a certified
training program in coach assisted chronic disease man-
agement. The training program includes the study of
key concepts in patient-centred communications, health
psychology, epidemiology of key targeted illnesses and
conditions, skills training in MI and behaviour change,
program evaluation, clinical outcome measurement and
the Happy Life Club™ intervention protocol.
The health coaches will aim to assist participants in
achieving the treatment targets as outlined in the Chinese
Guideline for Diabetes Prevention and Management [32],
with the primary goal of treatment of HbA1c of less than
7%. An intervention manual will be used in the study to
guide health coaches that utilises existing local guidelines
and recommendations (e.g. Dietary Guidelines for Chi-
nese Residents [49]). The initial step in each health
coaching session will be to set the agenda for the session
with the participant. This will be achieved by simply ask-
ing the participant “What would be helpful to talk about
today?” Once the participant identifies a key issue for dis-
cussion, health coaches will utilise their skills in MI by
assessing current behaviour in relation to the issue and
exploring the motivation and commitment for change. If
a participant displays a need and adequate commitment
to change, the health coaches will work with the partici-
pant to establish a goal for behaviour change that out-
lines where, when and how the behaviour change will be
performed.
In the first two months participants will receive two
face-to-face and four telephone coaching sessions per
month. The frequency of the sessions will decrease over
the 18 month intervention period as shown in Figure 2
such that in the last six months of the intervention, parti-
cipants will receive one face-to-face session per month
and one telephone session per three months. This reflects
the philosophy of the MI approach whereby over time
coach input diminished as the participants gain confi-
dence in self-management. While there is no preset time
frame for each health coaching session, it is anticipated
from the pilot study that the duration of each telephone
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to-face session approximately 30 minutes. Coaches will
record the length of each session.
In addition to health coaching, participants in the
intervention group will undergo assessment at baseline,
and again at 6, 12 and 18 months. All intervention parti-
cipants will be informed of their results.
Statistical analysis
Descriptive statistics will be used to summarise charac-
teristics of both CHCs and participants, with regards to
baseline characteristics and patterns of mean change
over time. Differences between the intervention and
control conditions, on both primary and secondary out-
comes, will then be evaluated using multilevel modelling
analysis [50]. Multilevel modelling refers to a family of
analytic techniques that are appropriate when data has a
‘nested’ structure, such as when individuals are nested
within groups (e.g., patients in hospitals). Repeated mea-
surements represent another type of hierarchical struc-
ture, whereby repeated measurements can be viewed as
nested within participants. Multilevel modelling techni-
ques, such as multilevel regression, have advantages
over alternative methods traditionally used to analyse
such repeated measures data (e.g., ANCOVA [51]). For
example, multilevel analysis uses data from all available
measurements to examine trajectories of change, rather
than focussing on a single wave of data such as the final
end-point measurement. Furthermore, multilevel analy-
sis can tolerate an ‘unbalanced’ data-set, whereby parti-
cipants can have varying numbers of measurements
which are irregularly spaced [52]. As such, multilevel
analysis does not exclude participants because of miss-
ing data or attrition from the study, and is thus consis-
tent with ‘intention to treat’ principles. Finally,
multilevel analysis can be adapted to incorporate more
than one type of nesting, as in cluster-randomised trials,
where: (1) repeated measurements are nested within
participants; and (2) participants are nested within
clusters (i.e., CHCs). Multilevel analysis explicitly mod-
els, and thus controls for variance at different levels of
the hierarchical structure, and has thus been recom-
mended for use with cluster-randomised trials [29].
Analyses will consider participant trajectories over
time, and evaluate whether these differ according to
levels of exposure to the intervention. Through multile-
vel analysis, variation in outcome scores will be parti-
tioned across three levels, including: (1) variation in
repeated measures within participants, modelled as a
function of the initial level (intercept), linear trajectory,
and Level-1 residual that may be autocorrelated and
heteroscedastic (although different models of the Level-
1 error covariance structure can be evaluated [53]);
(2) inter-individual variation in the intercept and trajec-
tory, specified as a function of the cluster mean and
Level-2 residual assumed to be independently and nor-
mally distributed; and (3) variation in cluster means for
both intercept and trajectory. The between-cluster varia-
tion in trajectory, specifically, is then modelled as a func-
tion of an intercept, Level-3 covariate (reflecting
exposure to the intervention), and residual. The test sta-
tistic for the parameter reflecting experimental condition
is used to test the null hypothesis of no treatment effect
[54]. One-sided tests will be used in all instances, and a
level of p < 0.05 will be used to evaluate statistical signifi-
cance of the primary outcome. Secondary analysis will
use the critical level of p < 0.001 to control Type I error
probabilities due to testing across multiple outcomes.
Qualitative study
Two qualitative studies will be conducted in parallel
with the cluster RCT:
1. Participant experience: Focus groups will be
undertaken with participants in each arm of the
RCT. Purposive sampling techniques will be utilised
to ensure a range of selected participants are
recruited into the study. We will ensure that the
Figure 2 Frequency of health coaching.
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tion, and participants who represent a range of self-
management behaviours and self-management skills
and confidence levels. The focus group schedule will
explore participants’ attitudes and experiences of the
health coach intervention.
2. Health coach experience: Focus groups will be
undertaken with health coaches from each CHC.
The focus group schedule will explore the barriers
and enablers to the delivery of the intervention
and the impact the intervention has had on their
professional role. In addition, all health coaches
will be completing diaries throughout the inter-
vention. After each coaching session they will
record their observation about the session includ-
ing goals set by the patient and their own reflec-
tions on the coaching process. These diaries will
be included in the analysis of the qualitative study
to evaluate the process of the implementation of
the intervention.
Data from the focus groups will be audio-taped, tran-
scribed verbatim, translated into English and entered
into NVIVO software [55] to organise the data. To
increase rigour, each transcript will be independently
coded line by line by two researchers. An inductive pro-
cess of thematic analysis, as described by Braun and
Clarke [56], will be employed to identify key issues and
themes within the data.
Discussion
This cluster RCT has been specifically tailored to the
Chinese health care system and has the ability to make
a large contribution to the evidence base for the man-
agement of patients with T2DM. It is hypothesised that
the health coaching intervention delivered in this study
will enhance the ability of patients to self-manage
T2DM, leading to improved clinical and psychosocial
outcomes, thus delaying diabetic complications. In addi-
tion, the components of metabolic syndrome and the
risk factors for cardiovascular disease will be assessed.
To our knowledge, this is the first trial that combines
both telephone and face-to-face health coaching in rela-
tion to T2DM management in China. Similar studies
have been conducted in other countries, however these
have primarily been telephone [57,58] or group based
interventions [59,60]. Furthermore, this study will
uniquely assess the benefits of intervention delivery for
three time periods (6, 12 and 18 months), providing evi-
dence for which is the optimal period of intervention.
This trial is being conducted in a real-world commu-
nity health setting in China. By implementing the
study in community health settings, this study empow-
ers and builds capacity within the existing workforce.
This approach embeds the study within community
health settings, thereby increasing the generalisability
of results [61].
The success of this study is reliant not only on the
capacity of the participants to engage in behaviour
change but also on the performance of individual health
coaches. According to the spirit of MI, the therapeutic
relationship is more like a partnership or companion-
ship than expert/recipient roles [18]. It is therefore
essential that health coaches are supported in their role.
Several approaches have been incorporated into the
intervention strategy to ensure coaches receive adequate
support: following initial MI training, regular meetings
will be scheduled with health coach coordinators; diaries
will be kept by each health coach; and a peer support
system will be implemented.
A na d d i t i o n a lc h a l l e n g ef o rt h i ss t u d yw i l lb et o
ensure that the back-translation of data collected
remains an accurate representation of the original ver-
sion. The use of two, independent, bilingual translators
will increase the chances that the original meaning has
been retained, will ensure literal accuracy and will help
to detect mistakes [62].
This trial, with a strong focus on self-management and
health coach support has the potential to be adapted to
other chronic diseases, as well as other regions of China.
The combination of both quantitative and qualitative
methods utilised in this study will allow for a more
comprehensive understanding of the implementation
process [63], and will provide additional information to
guide further research.
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